iiinova — where your digital self keeps evolving

DERM on RheumNow PODCAST (September 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. buff.ly/8ZtbzQZ

000

The GLP-1 Opportunity Cost in Rheumatology There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent. buff.ly/tXsf524

000

The weight is off, the DMARDs are off - now what? When treatments succeed, we have to plan the next steps. Let’s remember why we started and set new goals for life after the weight change. buff.ly/cAgYuG1

001

Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. buff.ly/EHG2yXz

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Objective We aimed to determine whether the short-term response to biologics in biologic-naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease…

000

Dr. John Cush @rheumnow.bsky.social · 01/10/2026

ARthritis & CAncer (ARCA) is Spanish retro study of 728 #RA pts w/ Hx of CA & Rx w/ biologics. W/ F/U of 11 022 yrs, new/recurrent CA was not incr (7.3/1000PYs) & = Pts Rx w/ csDMARDs (HRs 0.94; 0.73,1.21) & not incr w/ TNFi (0.94), IL-6i (1.03), CD20i (0.81), JAKi (0.6), ABA (0.74) buff.ly/GSD3ehs

000

Dr. John Cush @rheumnow.bsky.social · 01/10/2026

Obesity & Biologic Treatment Response Prepared for "The Obesity Imperative" campaign. buff.ly/krgxWwU

Dr. John Cush @rheumnow.bsky.social · 01/10/2026

Treatment for Obesity and Inflammation, but at what Cost? buff.ly/ZoAUyCz

000

Dr. John Cush @rheumnow.bsky.social · 30/09/2026

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein buff.ly/y9rQaOA

020

Dr. John Cush @rheumnow.bsky.social · 30/09/2026

Mediterranean Diet Lowers Incident RA Risk The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a MedDiet was associated with a substantially lower risk of incident RA, but not psoriasis. buff.ly/iQ0VJIb

000

Dr. John Cush @rheumnow.bsky.social · 30/09/2026

GCA international survey of 155 specialists (rheums 51%; ophthal 33%). w/ GCA dx, ASA started in only 15%; w/ 69.5% uncertain. w/ visual loss, 93% Rheums, 85% Ophthal Rx w/ IVGC, followed by oral. Uncertainty for IV versus po GC seen in 68.5% buff.ly/oY9uAs5

International practice patterns and beliefs concerning intravenous methylprednisolone and low-dose aspirin in giant cell arteritis - Eye

Eye - International practice patterns and beliefs concerning intravenous methylprednisolone and low-dose aspirin in giant cell arteritis

000

Obesity as a Risk Factor for Rheumatic Diseases buff.ly/P3Xg2eb

021

BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001). 1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later buff.ly/yDUiIxs

001

The Need for Weight Loss and Weight Gain in the ILD Clinic buff.ly/DgLwvMj

011

Dr. John Cush @rheumnow.bsky.social · 28/09/2026

Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & LDL buff.ly/VQNvSI9

000

52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. buff.ly/tsRr6gg

000

Dr. John Cush @rheumnow.bsky.social · 28/09/2026

Gabapentin Use Rose as Restrictions Fell, Study Shows Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed. buff.ly/Czoe2Oq

000

Dr. John Cush @rheumnow.bsky.social · 28/09/2026

Residual steroids doesnt preserve remission. Japan FRANK #RA registry 411/3,863 were in Boolean remission - 130 on GC vs 231 non-GC (1/3 on b/tsDMARDs). Roughly 1/3 flared to LDA @12 mos. Outcomes same for GC vs non-GC Rx pts. buff.ly/ZPnGGqf

000

Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications buff.ly/Oj3vuij

012

Prescribing New GLP-1-Based Therapies buff.ly/strzaZX

021

Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 buff.ly/7rE7jqd

000

Dr. John Cush @rheumnow.bsky.social · 25/09/2026

Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits buff.ly/pGQpIDB~

000

Do You Have to be Overweight for GLP-1s to Work? buff.ly/z5mLbOO

000

Dr. John Cush @rheumnow.bsky.social · 25/09/2026

TNR: Obesity Treatment & Safety buff.ly/ekuQViw

000

Dr. John Cush @rheumnow.bsky.social · 24/09/2026

2024 death rates from unintentional falls among adults≥65 yrs were 74.8/100K for men (66.6 women) Rates were higher for men > women. Fall death rates incr w/ age: highest ≥85 years. buff.ly/OTJQQ2f

Dr. John Cush @rheumnow.bsky.social · 24/09/2026

Prescribing New GLP-1-Based Therapies buff.ly/strzaZX

000

Dr. John Cush @rheumnow.bsky.social · 24/09/2026

Amgen announced topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep (CD40L antagonist fusion protein) in adult Sjögren's dz w/ positive ESSDAI results at wk 48 buff.ly/lBDTGD0

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE| Amgen

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity

It’s almost time. 🔥 Registration for RheumNow Live 2027 opens OCTOBER 1. Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice. 📅 Jan 30–31, 2027 📍 Dallas + Online

000

Retrospective review of 33 referred pts w/ Recurrent fever w/ MSK & skin Sxs, assessed by NGS. NLRP1 had FMF-like Dz; NLRP recurrent fevers w/ mucocutaneous; NLRP12 periodic fevers w/ MP/EN rash; NLRC4 episodic systemic inflammation GI Sxs & atypical skin rash buff.ly/OGfUkzH

Beyond NLRP3: expanding the spectrum of NLR-associated autoinflammatory diseases

AbstractObjectives. Gain-of-function mutations in NLRP3 represent the prototypical cause of inflammasome-driven systemic autoinflammatory diseases(SAIDs).

000

Southern Israel study (2009-24) shows fibromyalgia prevalence Incr from 1.04% to 3.88%, esp 30-59 yrs; more males, w/ more Psych comorbidities; fewer hospitalizations & specialist visits but increased imaging. More use of pregabalin, duloxetine, & gabapentin. buff.ly/hmgpsXT

000

Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 cont either CZP or ADA throughout PREG. Rates of miscarriage, cong anomalies, = to gen population buff.ly/5lxIyGY

Biologic Therapy in Pregnant Women with Plaque Psoriasis: A Narrative Review of Maternal and Fetal Safety Considerations | MDPI

Background: Psoriasis in pregnancy is a highly prevalent inflammatory condition worldwide, with patients asking how the disease itself, as well as the medications that they take, would affect the…

000

Indian Single center retrospective study of 28 children ≤18 yrs tested w/ 18F-FDG-PET/MR for pyrexia (PUO). 25% Dx w/ pre-stenotic TAKayasu (mean 13.9 yrs), & 20/21 alternative Dxs. All had Sxs & high ESR/CRP; all Rx w/ GC & MMF, 3 w/ biologics buff.ly/ffKyCuB

Frontiers | FDG-PET/MR in paediatric pyrexia of unknown origin: early detection of Takayasu arteritis—a single-centre experience

Pyrexia of unknown origin (PUO) in children presents a significant diagnostic challenge owing to its broad and heterogeneous aetiology. Among autoimmune caus...

000

Early RA Referral Clinics Work (9.18.2026) Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com buff.ly/NPZQxMG

000

🚨 Registration opens October 1! RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting. 📍 Dallas + Online 📅 January 30–31, 2027 🎓 High-impact CME. Expert faculty. Real-world rheumatology. The rheumatology meeting that sets the tone for the year ahead.

000

QD Clinic: GLP-1s and History of Thyroid Cancer? Daric Mueller, PA-C, St. Clair Shores, MI, presents this case as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. buff.ly/MU8hyt2

Obesity in Rheumatic Diseases: More than just a Comorbidity buff.ly/YhMXna5

Estimated > 7million Americans (~1/3 US GLP1 Rxs) get GLP-1 drugs from online compounding source- but these are not FDA approved. They maybe cheaper, but dosing/quality is suspect. FDA needs to close the 503B loophole to outlaw these copycat Rxs buff.ly/xezDWaJ

What compounded GLP-1s mean for patient safety

Millions of Americans use compounded versions of GLP-1s to save money. Stanford Medicine experts explain what makes them different from FDA-approved versions.

000

Metabolomic/proteomics w/ cardiac MRI & longitudinal outcomes in 488079 UK Biobank pts shows chronic systemic inflammation assoc w/ reduced LV volumes, incr CV risk (cytokines, GFs, IL-1, TNF as potential mediators) buff.ly/3SCOlsg